noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

United States District Court for[...]

Opinion: Doc No. 7 - Case: Civil Case No. 25-3255Aich v. Reno County[...]
FAS - Foreign Agricultural Service

Turkey: Biotechnology and Other New Production Technologies Annual
FAS - Foreign Agricultural Service

Spain: Biotechnology and Other New Production Technologies Annual

Healthcare

Cytokinetics Incorporated

12/12/2025 | Press release | Distributed by Public on 12/12/2025 07:54

Material Event (Form 8-K)

Item 8.01 Other Events.

On December 12, 2025, Cytokinetics, Incorporated ("Cytokinetics" or the "Company") announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO® (aficamten), a cardiac myosin inhibitor, for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy in adult patients. A final decision is anticipated from the European Commission in the first quarter of 2026.

Cytokinetics Incorporated published this content on December 12, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on December 12, 2025 at 13:54 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]